New division integrates material science, predictive modeling, and advanced analytics to accelerate pharmaceutical development from molecule to market.
St. Louis, Missouri — April 22, 2026 — TaBlitz today announced the launch of TaBlitz Labs, a new AI-powered CDMO partner designed to support pharmaceutical development teams across the entire oral solid dosage (OSD) lifecycle—from early-stage formulation through scale-up and manufacturing readiness.
Built on the foundation of TaBlitz’s predictive modeling platform, TaBlitz Labs combines material science, micromeritic characterization, compression physics, and advanced analytical technologies to help pharmaceutical companies develop robust, manufacturable tablet formulations faster and with greater confidence.
As drug pipelines increasingly include more complex molecules and challenging formulations, development teams face growing pressure to reduce timelines while minimizing risk. TaBlitz Labs was created to address this challenge by integrating predictive insight with hands-on development support, helping teams identify potential issues earlier in the development process.
“Too often, the first time a development team truly understands their formulation is when something goes wrong during scale-up,” said Michael Ruch, Co-Founder of TaBlitz. “TaBlitz Labs was built to change that. By combining predictive modeling with deep material science expertise, we help teams understand how their formulations will behave long before they reach the manufacturing floor.”
A New Approach to Oral Solid Dosage Development
Traditional drug development workflows often rely on iterative experimentation to identify formulation and manufacturing risks. TaBlitz Labs introduces a more integrated approach by connecting material characterization, compression analysis, advanced imaging, and predictive modeling into a unified development strategy.
Through this model, TaBlitz Labs supports pharmaceutical teams with services including:
Material science and micromeritic characterization
Compression behavior analysis and compaction profiling
Predictive modeling for manufacturability risk
Advanced tablet analysis including CT imaging
Formulation optimization and troubleshooting
Development support from early formulation through manufacturing readiness
This integrated approach enables teams to make more informed decisions earlier in the development process, helping reduce trial-and-error experimentation and improving the likelihood of successful scale-up.
Supporting Virtual Drug Companies, CDMOs, and Development Teams
TaBlitz Labs is designed to support a broad range of organizations involved in oral solid dosage development, including virtual drug companies (VDCs), contract development and manufacturing organizations (CDMOs), and internal pharmaceutical R&D teams.
For virtual drug companies operating asset-light models, TaBlitz Labs provides access to specialized material science expertise and advanced analytical capabilities without the need to build internal infrastructure.
For CDMOs and pharmaceutical manufacturers, the platform helps accelerate formulation development and troubleshoot complex tableting challenges by bringing deeper insight into the physics driving tablet performance.
Advancing the Future of Pharmaceutical Development
With the launch of TaBlitz Labs, the company expands its mission of helping pharmaceutical teams move beyond traditional trial-and-error development workflows toward data-driven, predictive approaches to formulation and manufacturing.
“Our goal is simple,” Ruch added. “Help development teams solve complex formulation challenges faster, reduce costly surprises during scale-up, and ultimately accelerate the path from molecule to market.”
About TaBlitz
TaBlitz is a pharmaceutical technology company focused on advancing oral solid dosage development through predictive modeling, material science insights, and advanced analytical tools. The TaBlitz platform helps formulation scientists better understand powder behavior, compression physics, and tablet manufacturability earlier in the development process. With the launch of TaBlitz Labs, the company expands its capabilities to provide integrated development support for pharmaceutical teams seeking to accelerate formulation development and improve manufacturing outcomes.
Next step
Learn how TaBlitz Labs can support your OSD program from early insight through manufacturing readiness.